Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 13/20 | 0.43 |
| ▸ | PPARA | Q07869 | 7/20 | 0.43 |
| ▸ | SMO | Q99835 | 1/20 | 0.41 |
| ▸ | PPARD | Q03181 | 2/20 | 0.36 |
| ▸ | TEAD1 | P28347 | 1/20 | 0.36 |
| ▸ | TEAD4 | Q15561 | 1/20 | 0.36 |
| ▸ | TEAD2 | Q15562 | 1/20 | 0.36 |
| ▸ | TEAD3 | Q99594 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10003374 | 0.94 | SMO (0.47) | PPARGPPARASMOPPARDTEAD1 | |
| SCHEMBL10004461 | 0.90 | PPARG (0.39) | PPARGPPARASMOPPARDTEAD1 | |
| SCHEMBL10003872 | 0.90 | SMO (0.40) | PPARGPPARASMO | |
| SCHEMBL10004554 | 0.90 | HKDC1 (0.39) | PPARGPPARASMO | |
| SCHEMBL10004814 | 0.89 | PPARG (0.40) | PPARGPPARASMO | |
| SCHEMBL10004667 | 0.88 | MEN1 (0.43) | PPARGPPARA | |
| SCHEMBL10004618 | 0.87 | SMO (0.51) | PPARGPPARASMO | |
| SCHEMBL10003908 | 0.86 | SMO (0.47) | PPARGPPARASMO | |
| SCHEMBL10003740 | 0.85 | SMO (0.45) | SMO | |
| SCHEMBL10003999 | 0.85 | SMO (0.46) | PPARGPPARASMO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2471790-B1 | FUSED HETEROCYCLIC RING DERIVATIVE AND USE THEREOF | TAKEDA PHARMACEUTICAL (JP) | 2015-03-18 | — | — | EP | disclosed |
| US-8907089-B2 | Fused heterocyclic ring derivative and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-12-09 | — | — | US | disclosed |
| US-20120220570-A1 | FUSED HETEROCYCLIC RING DERIVATIVE AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-08-30 | — | — | US | disclosed |
| EP-2471790-A1 | FUSED HETEROCYCLIC RING DERIVATIVE AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2012-07-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120220570-A1 | FUSED HETEROCYCLIC RING DERIVATIVE AND USE THEREOF | SMO, GLI1, SHH | PPARG 1436/4885PPARA 1309/4885SMO 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.